Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies
Ma, Julian K-C.
Pujol Ferrer, Merardo
MetadataShow full item record
Molecular Pharming, the production of recombinant pharmaceuticals through plant biotechnology, has the potential to transform the biologics sector of the pharmaceutical industry. More fascinating however, is how it might be used to improve access to modern medicines, and improve health of the poor in developing countries and emerging economies. Although improving global health through molecular pharming has been discussed for at least two decades, little progress has actually been made. In this manuscript, a four point plan is described to maximise the opportunity for molecular pharming to provide solutions. These are (i) to identify and prioritise important drug targets that are relevant to the poor; (ii) to support research and development partners in low to middle income countries to develop local expertise, transfer technology and build capacity; (iii) to increase collaboration between regulatory bodies to enable national regulatory frameworks to be developed in low to middle income countries; and (iv) to promote intellectual property management approaches that include socially responsible licensing. An existing case study is described to illustrate how this might be achieved.
Is part ofPlant Biotechnology Journal, 2013, vol. 11, núm. 9, p. 1029-1033
European research projects
Showing items related by title, author, creator and subject.
Impact of Emerging Technologies on Virgin Olive Oil Processing, Consumer Acceptance, and the Valorization of Olive Mill Wastes Pérez Bosch, Maria; López-Yerena, Anallely; Lozano-Castellón, Julián; Olmo-Cunillera, Alexandra; Lamuela Raventós, Rosa Ma.; Martín Belloso, Olga; Vallverdú i Queralt, Anna (MDPI, 2021-03-09)There is a growing consumer preference for high quality extra virgin olive oil (EVOO) with health-promoting and sensory properties that are associated with a higher content of phenolic and volatile compounds. To meet this ...
Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants Ma, Julian K-C.; Drossard, Jürgen; Lewis, David; Altmann, Friedrich; Boyle, Julia; Christou, Paul; Cole, Tom; Dale, Philip; van Dolleweerd, Craig J.; Isitt, Valerie; Katinger, Dietmar; Lobedan, Martin; Mertens, Hubert; Paul, Mathew; Rademacher, Thomas; Sack, Markus; Hundleby, Penelope A. C.; Stiegler, Gabriela; Stöger, Eva; Twyman, Richard M.; Vcelar, Brigitta; Fischer, Rainer (Wiley, 2015)Although plant biotechnology has been widely investigated for the production of clinical-grade monoclonal antibodies, no antibody products derived from transgenic plants have yet been approved by pharmaceutical regulators ...
Analysis of trade‐offs between biodiversity, carbon farming and agricultural development in Northern Australia reveals the benefits of strategic planning Morán-Ordóñez, Alejandra; Whitehead, Amy L.; Luck, Gary W.; Cook, Garry D.; Maggini, Ramona; Fitzsimons, James A.; Wintle, Brendan A. (Wiley, 2016-06-06)Australia's northern savannas are one of the few remaining large and mostly intact natural areas on Earth. However, their biodiversity and ecosystem values could be threatened if proposed agricultural development proceeds. ...